Among 977 patients with reliable liver stiffness measurements, 154 had values ≥ 8.0 kPa, and 49 had values > 12.0 kPa, suggesting liver fibrosis and advanced disease, respectively.

This cross-sectional study conducted in one hospital in China included 432 patients hospitalized due to T2D and its complications from January 2018 to April 2020 (median T2D duration, 6 years ...

The 2017 to 2020 (n=7683) and 2021 to 2023 (n=5470) NHANES cohorts, of whom 51% and 50% were women, 62.3% and 60.1% were White, and 13.8% and 13.8% had T2D, respectively, had mean (SD) ages of 47 ...

Novo Nordisk surges as Wegovy secures FDA approval for MASH, marking a breakthrough in liver care and expanding its blockbuster reach.

The updated European guidelines for managing metabolic dysfunction-associated steatotic liver disease (MASLD) mark a significant shift in hepatology practice. Jointly issued by the EASL, EASD, and ...

New European guidelines redefine Metabolic dysfunction-associated steatotic liver disease (MASLD) care, offering clearer ...

Looking at combined benefits, a third of patients taking semaglutide were able to see both resolution of steatohepatitis and reduction of liver fibrosis (32.7%), compared with 16.1% of patients ...

The drug received accelerated approval for use in patients with metabolic dysfunction-associated steatohepatitis (MASH).

For example, in the SELECT trial (17,600 patients with cardiovascular disease and obesity but without T2D), weekly subcutaneous Semaglutide (2.4 mg) reduced the risk of major adverse ...

MASLD rates have decreased, whereas liver fibrosis and cirrhosis rates have increased among US patients with type 2 diabetes since 2017.